As members of this committee, we are well positioned to validate the clinical utility of the consensus DSC-MRI protocol across multiple institutions and major MRI vendors. To improve the repeatability, accuracy and multi-site consistency of DSC- MRI, the National Brain Tumor Society (NBTS) formed an international committee of leading DSC-MRI investigators to standardize DSC-MRI methodology. The translation of clinical DSC-MRI across multiple institutions remains challenging due to site-specific acquisition and analysis variability. To overcome these limitations, DSC-MRI evaluation of relative cerebral blood volume (rCBV) has been proposed for response assessment of high-grade gliomas (HGG) and differentiation of tumor recurrence from PTRE. A definitive imaging-based diagnosis that obviates the need for surgical biopsy would be beneficial.
![photo-dsc protocol photo-dsc protocol](https://jkrouwer.files.wordpress.com/2021/12/dsc03847-edit.jpg)
Its inability to reliably monitor treatment response and differentiate tumor recurrence from posttreatment radiation effect (PTRE) often forces clinicians to rely upon surgical biopsy for definitive diagnosis, which increases cost, morbidity, and resource utilization. Contrast-enhanced MRI is the clinical imaging standard for guiding nearly all aspects of brain tumor management.
#Photo dsc protocol trial
The overall goal of this early phase, multi-site clinical trial is to validate and demonstrate the clinical utility of a consensus protocol for dynamic susceptibility contrast (DSC) MRI.